Rep. Marjorie Taylor Greene Buys Eli Lilly and Company (NYSE:LLY) Shares

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on May 19th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on May 14th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 5/16/2025.
• Purchased $1,001 - $15,000 in shares of Impinj NASDAQ: PI on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of Corning NYSE: GLW on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of Cardinal Health NYSE: CAH on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of Chevron NYSE: CVX on 5/14/2025.
• Purchased $15,001 - $50,000 in shares of UnitedHealth Group NYSE: UNH on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of Blackstone NYSE: BX on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/14/2025.
• Purchased $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 5/14/2025.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $22.73 during mid-day trading on Wednesday, reaching $724.28. The company had a trading volume of 4,054,290 shares, compared to its average volume of 3,606,606. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a market cap of $686.43 billion, a price-to-earnings ratio of 61.85, a PEG ratio of 1.40 and a beta of 0.48. The business's 50-day simple moving average is $795.44 and its 200 day simple moving average is $804.82.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the previous year, the business posted $2.58 EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently made changes to their positions in LLY. Grassi Investment Management boosted its stake in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company's stock valued at $61,383,000 after purchasing an additional 225 shares in the last quarter. Elevate Capital Advisors LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $262,000. Capital & Planning LLC raised its position in shares of Eli Lilly and Company by 15.6% during the fourth quarter. Capital & Planning LLC now owns 481 shares of the company's stock worth $371,000 after acquiring an additional 65 shares during the last quarter. Woodstock Corp raised its position in shares of Eli Lilly and Company by 1.4% during the fourth quarter. Woodstock Corp now owns 8,268 shares of the company's stock worth $6,383,000 after acquiring an additional 117 shares during the last quarter. Finally, Yarger Wealth Strategies LLC raised its position in shares of Eli Lilly and Company by 30.1% during the fourth quarter. Yarger Wealth Strategies LLC now owns 450 shares of the company's stock worth $347,000 after acquiring an additional 104 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LLY. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Finally, UBS Group reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.